Onconetix subsidiary Proteomedix names co-founder Ralph Schiess to board

Reuters2026/08/05 12:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Onconetix subsidiary Proteomedix appointed co-founder Ralph Schiess to its board.
Shareholders re-elected Thomas Meier as board chairman for a one-year term at the June 22 annual meeting.
Move adds Proclarix co-developer Schiess as Proteomedix advances its CE-IVD prostate cancer blood test.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050830PRIMZONEFULLFEED9804104) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Onconetix subsidiary Proteomedix names co-founder Ralph Schiess to board

You may also like

Crypto prices